SuperworthKrystal Biotech EPS KRYS
Diluted earnings per share by quarter and over the last twelve months, from 2016.
- Last 12 months, to Jun 30, 2026
- $7.98
- Latest quarter, Q2 FY26
- $1.79
- +39% on a year earlier
- Fiscal year 2025
- $6.85
- +129% on the year before
Krystal Biotech's earnings per share was $7.98 over the twelve months to Jun 30, 2026, up 62% on a year earlier.
In its latest quarter, Q2 FY26, it was $1.79, up 39% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $6.85 | +129% |
| FY2024 | $2.99 | +3638% |
| FY2023 | $0.08 | n/a |
| FY2022 | −$5.51 | n/a |
| FY2021 | −$3.12 | n/a |
| FY2020 | −$1.70 | n/a |
| FY2019 | −$1.22 | n/a |
| FY2018 | −$0.96 | n/a |
| FY2017 | −$1.76 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $1.79 | +39% | $7.98 | |
| Q1 FY26 | $1.83 | +53% | $7.48 | |
| Q4 FY25 | $1.70 | +12% | $6.85 | |
| Q3 FY25 | $2.66 | +192% | $6.67 | |
| Q2 FY25 | $1.29 | +143% | $4.92 | |
| Q1 FY25 | $1.20 | +3900% | $4.16 | |
| Q4 FY24 | $1.52 | +407% | $2.99 | |
| Q3 FY24 | $0.91 | −67% | $1.77 | |
| Q2 FY24 | $0.53 | n/a | $3.65 | |
| Q1 FY24 | $0.03 | n/a | $1.87 | |
| Q4 FY23 | $0.30 | n/a | $0.08 | |
| Q3 FY23 | $2.79 | n/a | −$1.47 |
Against its peers
Companies in Biotechnology nearest Krystal Biotech's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| KRYSKrystal Biotech | $7.98 | +62% a year |
| RGENRepligen | $0.73 | |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| EXELExelixis | $3.18 | +53% a year |
| INCYIncyte | $7.85 | +78% a year |
| UTHRUnited Therapeutics | $27.95 | +9% a year |
| ALNYAlnylam Pharmaceuticals | $5.93 | |
| ADMAAdma Biologics | $0.70 | −18% a year |
| VCELVericel | $0.46 | +283% a year |
| Peer median | $3.27 |
Where Krystal Biotech ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Krystal Biotech
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.